Parallax Volatility Advisers
MTNB icon

Parallax Volatility Advisers’s Matinas BioPharma MTNB Stock Holding History

Parallax Volatility Advisers’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-323
Closed -$19K – 3525
2017
Q4 		$19K Buy
+323
New +$20.8K ﹤0.01% 3684

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWMG
Alliance Wealth Management Group Flemington, New Jersey $457M AUM 12.13% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Parallax Volatility Advisers's MTNB Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Matinas BioPharma (MTNB) in Q1 2018, closing a stake of 323 shares — an estimated $19K sold.

Parallax Volatility Advisers first reported a position in MTNB in Q4 2017 and held it in 1 quarter. The position peaked at $19K in Q4 2017. 45 funds tracked by Wall St. Rank hold MTNB as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Matinas BioPharma position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 323 Matinas BioPharma shares in Q1 2018, an estimated $19K.
  • Parallax Volatility Advisers first reported a position in Matinas BioPharma in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Matinas BioPharma position peaked at $19K in Q4 2017.
  • 45 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.